[Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals (TARS), reported sales of common stock on 08/11/2025 as shown on this Form 4. The filing lists dispositions of 53,635 and 6,000 shares and shows a transaction price of $50 where indicated, with reported beneficial ownership of 818,106 shares following the transactions. The sales were effected automatically under a Rule 10b5-1 trading plan adopted December 12, 2024. Azamian is trustee of the Bobak Azamian Living Trust (established April 16, 2018) and has voting and dispositive power over the trust shares. The Form 4 was signed by an attorney-in-fact on 08/13/2025.

Insights

Financial Analyst

TL;DR: Routine, plan-based insider dispositions; the Form 4 documents scheduled sales rather than ad hoc trading.

The Form 4 records dispositions of common stock by CEO Bobak Azamian on 08/11/2025 under a Rule 10b5-1 trading plan adopted December 12, 2024. The filing explicitly lists amounts of 53,635 and 6,000 shares and shows a price of $50 where stated, leaving reported beneficial ownership of 818,106 shares. As a disclosure of insider sales executed under a documented plan, the filing provides transparency on timing and amounts but does not include operational or financial performance information.

Corporate Governance Expert

TL;DR: Disclosure is compliant and clarifies trustee authority and use of a 10b5-1 plan for the sales.

The filing identifies Azamian as a director and as President/CEO and Board Chair and states he is trustee of the Bobak Azamian Living Trust (established April 16, 2018) with voting and dispositive power over trust shares. It also states the sales were effected automatically under a Rule 10b5-1 plan. The form is signed by an attorney-in-fact, consistent with authorized filing procedures. This provides investors clear information on the legal basis and authority for the reported dispositions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azamian Bobak R.

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President/CEO and Board Chair

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		S(1)		6,000	D	$50	818,106	I	By the Bobak Azamian Living Trust established April 16, 2018(2)
Common Stock								53,635	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024.

2. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for TARS report?

The Form 4 reports dispositions of common stock by Bobak R. Azamian dated 08/11/2025, executed under a Rule 10b5-1 trading plan adopted December 12, 2024.

How many TARS shares are listed as disposed on the Form 4?

The filing lists dispositions of 53,635 shares and 6,000 shares as shown on the Form 4.

At what price were the TARS shares reported on the Form 4?

The Form 4 shows a transaction price of $50 where indicated in the reported entries.

What was Azamian's beneficial ownership after the reported transactions?

The filing reports reported beneficial ownership of 818,106 shares following the transactions.

What is Azamian's role at Tarsus Pharmaceuticals (TARS)?

The Form 4 identifies Azamian as a Director and as an Officer with the title President/CEO and Board Chair.

Were the sales discretionary or plan-based?

The Form 4 states the sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.